Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.

Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun-Turgut D, Poston K, Arnedo V, Frasier M, Sherer T; Parkinson's Progression Markers Initiative.

Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477. doi: 10.1002/acn3.644. eCollection 2018 Dec.

2.

Cognition among individuals along a spectrum of increased risk for Parkinson's disease.

Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D; Parkinson’s Progression Markers Initiative.

PLoS One. 2018 Aug 20;13(8):e0201964. doi: 10.1371/journal.pone.0201964. eCollection 2018.

3.

Finding useful biomarkers for Parkinson's disease.

Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson MR, Dawson TM, Dewey R, Foroud T, Frasier M, German D, Gwinn K, Huang X, Kopil C, Kremer T, Lasch S, Marek K, Marto JA, Merchant K, Mollenhauer B, Naito A, Potashkin J, Reimer A, Rosenthal LS, Saunders-Pullman R, Scherzer CR, Sherer T, Singleton A, Sutherland M, Thiele I, van der Brug M, Van Keuren-Jensen K, Vaillancourt D, Walt D, West A, Zhang J.

Sci Transl Med. 2018 Aug 15;10(454). pii: eaam6003. doi: 10.1126/scitranslmed.aam6003. Review.

PMID:
30111645
4.

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.

Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K; Parkinson's Progression Marker Initiative*.

Mov Disord. 2018 May;33(5):771-782. doi: 10.1002/mds.27361. Epub 2018 Mar 23.

5.

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.

Simuni T, Caspell-Garcia C, Coffey CS, Weintraub D, Mollenhauer B, Lasch S, Tanner CM, Jennings D, Kieburtz K, Chahine LM, Marek K.

J Neurol Neurosurg Psychiatry. 2018 Jan;89(1):78-88. doi: 10.1136/jnnp-2017-316213. Epub 2017 Oct 6.

6.

Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease.

Amara AW, Chahine LM, Caspell-Garcia C, Long JD, Coffey C, Högl B, Videnovic A, Iranzo A, Mayer G, Foldvary-Schaefer N, Postuma R, Oertel W, Lasch S, Marek K, Simuni T; Parkinson’s Progression Markers Initiative.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):653-662. doi: 10.1136/jnnp-2016-315023. Epub 2017 May 29.

PMID:
28554959
7.

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease.

Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu IW, Zhang Y, Nalls M, Singleton A, Shaw LA, Kang JH, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, Weintraub D; Parkinson’s Progression Markers Initiative (PPMI).

PLoS One. 2017 May 17;12(5):e0175674. doi: 10.1371/journal.pone.0175674. eCollection 2017.

8.

Antibody Neutralization of CXCL10 in Vivo Is Dependent on Binding to Free and Not Endothelial-bound Chemokine: IMPLICATIONS FOR THE DESIGN OF A NEW GENERATION OF ANTI-CHEMOKINE THERAPEUTIC ANTIBODIES.

Bonvin P, Gueneau F, Buatois V, Charreton-Galby M, Lasch S, Messmer M, Christen U, Luster AD, Johnson Z, Ferlin W, Kosco-Vilbois M, Proudfoot A, Fischer N.

J Biol Chem. 2017 Mar 10;292(10):4185-4197. doi: 10.1074/jbc.M116.745877. Epub 2017 Jan 30.

9.

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease.

Simuni T, Long JD, Caspell-Garcia C, Coffey CS, Lasch S, Tanner CM, Jennings D, Kieburtz KD, Marek K; PPMI Investigators.

Ann Clin Transl Neurol. 2016 May 17;3(7):482-94. doi: 10.1002/acn3.317. eCollection 2016 Jul.

10.

How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?

Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Tanner C, Marek K; PPMI Investigators.

Parkinsonism Relat Disord. 2016 Jul;28:62-7. doi: 10.1016/j.parkreldis.2016.04.027. Epub 2016 Apr 23.

PMID:
27132498
11.

Novel recruitment strategy to enrich for LRRK2 mutation carriers.

Foroud T, Smith D, Jackson J, Verbrugge J, Halter C, Wetherill L, Sims K, Xin W, Arnedo V, Lasch S, Marek K; Parkinson's Progression Markers Initiativea.

Mol Genet Genomic Med. 2015 Sep;3(5):404-12. doi: 10.1002/mgg3.151. Epub 2015 May 6.

12.

Anti-CD3/Anti-CXCL10 Antibody Combination Therapy Induces a Persistent Remission of Type 1 Diabetes in Two Mouse Models.

Lasch S, Müller P, Bayer M, Pfeilschifter JM, Luster AD, Hintermann E, Christen U.

Diabetes. 2015 Dec;64(12):4198-211. doi: 10.2337/db15-0479. Epub 2015 Aug 20.

13.

Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study.

Simuni T, Caspell-Garcia C, Coffey C, Chahine LM, Lasch S, Oertel WH, Mayer G, Högl B, Postuma R, Videnovic A, Amara AW, Marek K; PPMI Sleep Working group on behalf of the PPMI Investigators.

Mov Disord. 2015 Sep;30(10):1371-81. doi: 10.1002/mds.26248. Epub 2015 Jun 11.

14.

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.

Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA; Parkinson's Progression Markers Initiative.

Mov Disord. 2015 Jun;30(7):919-27. doi: 10.1002/mds.26170. Epub 2015 Mar 4.

15.

Functional redundancy of CXCR3/CXCL10 signaling in the recruitment of diabetogenic cytotoxic T lymphocytes to pancreatic islets in a virally induced autoimmune diabetes model.

Coppieters KT, Amirian N, Pagni PP, Baca Jones C, Wiberg A, Lasch S, Hintermann E, Christen U, von Herrath MG.

Diabetes. 2013 Jul;62(7):2492-9. doi: 10.2337/db12-1370. Epub 2013 Feb 22.

16.

Objective structured assessment of technical skills for repair of fourth-degree perineal lacerations.

Siddiqui NY, Stepp KJ, Lasch SJ, Mangel JM, Wu JM.

Am J Obstet Gynecol. 2008 Dec;199(6):676.e1-6. doi: 10.1016/j.ajog.2008.07.054.

PMID:
19084100
17.

Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction.

Schurr PG, Yekebas EF, Kaifi JT, Lasch S, Strate T, Kutup A, Cataldegirmen G, Bubenheim M, Pantel K, Izbicki JR.

J Surg Oncol. 2006 Sep 15;94(4):307-15.

PMID:
16917878
18.

BR96 conjugates of highly potent anthracyclines.

King HD, Staab AJ, Pham-Kaplita K, Yurgaitis D, Firestone RA, Lasch SJ, Trail PA.

Bioorg Med Chem Lett. 2003 Jul 7;13(13):2119-22.

PMID:
12798317
19.

Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains.

King HD, Dubowchik GM, Mastalerz H, Willner D, Hofstead SJ, Firestone RA, Lasch SJ, Trail PA.

J Med Chem. 2002 Sep 12;45(19):4336-43.

PMID:
12213074
20.

Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity.

Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K, Knipe JO, Lasch SJ, Trail PA.

Bioconjug Chem. 2002 Jul-Aug;13(4):855-69.

PMID:
12121142
21.

Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages.

Dubowchik GM, Radia S, Mastalerz H, Walker MA, Firestone RA, Dalton King H, Hofstead SJ, Willner D, Lasch SJ, Trail PA.

Bioorg Med Chem Lett. 2002 Jun 3;12(11):1529-32.

PMID:
12031335
22.

Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.

Trail PA, Willner D, Bianchi AB, Henderson AJ, TrailSmith MD, Girit E, Lasch S, Hellström I, Hellström KE.

Clin Cancer Res. 1999 Nov;5(11):3632-8.

23.

Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates.

King HD, Yurgaitis D, Willner D, Firestone RA, Yang MB, Lasch SJ, Hellström KE, Trail PA.

Bioconjug Chem. 1999 Mar-Apr;10(2):279-88.

PMID:
10077478
24.

Using continuous quality improvement to improve diabetes care in populations: the IDEAL model. Improving care for Diabetics through Empowerment Active collaboration and Leadership.

Solberg LI, Reger LA, Pearson TL, Cherney LM, O'Connor PJ, Freemen SL, Lasch SL, Bishop DB.

Jt Comm J Qual Improv. 1997 Nov;23(11):581-92. Review.

PMID:
9407262
25.

Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.

Trail PA, Willner D, Knipe J, Henderson AJ, Lasch SJ, Zoeckler ME, TrailSmith MD, Doyle TW, King HD, Casazza AM, Braslawsky GR, Brown J, Hofstead SJ, Greenfield RS, Firestone RA, Mosure K, Kadow KF, Yang MB, Hellström KE, Hellström I.

Cancer Res. 1997 Jan 1;57(1):100-5.

26.

Continuous quality improvement can improve glycemic control for HMO patients with diabetes.

O'Connor PJ, Rush WA, Peterson J, Morben P, Cherney L, Keogh C, Lasch S.

Arch Fam Med. 1996 Oct;5(9):502-6.

PMID:
8930220
27.

(6-Maleimidocaproyl)hydrazone of doxorubicin--a new derivative for the preparation of immunoconjugates of doxorubicin.

Willner D, Trail PA, Hofstead SJ, King HD, Lasch SJ, Braslawsky GR, Greenfield RS, Kaneko T, Firestone RA.

Bioconjug Chem. 1993 Nov-Dec;4(6):521-7.

PMID:
7508268
28.

Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.

Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellström I, Hellström KE.

Science. 1993 Jul 9;261(5118):212-5. Erratum in: Science 1994 Feb 25;263(5150):1076.

PMID:
8327892
29.

Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.

Trail PA, Willner D, Lasch SJ, Henderson AJ, Greenfield RS, King D, Zoeckler ME, Braslawsky GR.

Cancer Res. 1992 Oct 15;52(20):5693-700.

Supplemental Content

Support Center